Exendin-4 Fc fusion

JY09 is a long-acting GLP-1 receptor agonist from Beijing Dongfang Biotech, structurally a dimer of exendin-4 fused to a human IgG Fc fragment, dosed bi-weekly by subcutaneous injection, in Phase 3 for type 2 diabetes [1]. The commercially decisive trial (NCT06257966) is a 600-patient three-arm head-to-head against weekly dulaglutide (Trulicity) on a metformin background, with HbA1c as the primary endpoint [1]. The bi-weekly schedule (half the injection frequency of dulaglutide and semaglutide) is the most distinctive feature versus the competitive set. Readout was expected Q2 2026, putting topline data at or near release.

Novel compound, never approved. Two Phase 3 trials sit as active not recruiting on ClinicalTrials.gov: NCT06254014 (n=270, placebo-controlled) and NCT06257966 (n=600 in a 1:1:1 design with JY09 1.2 mg bi-weekly, JY09 2.4 mg bi-weekly with a two-week dose escalation, and dulaglutide arms, on a metformin background) [1][2]. Both list HbA1c reduction as the primary endpoint. Sponsor is Beijing Dongfang Biotech, a private Chinese firm. No FDA breakthrough therapy, fast track, orphan, or priority review designations are listed, which fits the profile: type 2 diabetes does not qualify as unmet need under FDA criteria, and the program is China-focused rather than built for an FDA registration package. Earlier-phase work included a Phase 1 PK/PD/tolerability study (NCT04354090, n=41, completed) and a separate drug-drug interaction and QT study in overweight Chinese subjects (NCT06247748, n=28, completed) [3][4]. Published Phase 1 data appeared in 2020 in the International Journal of Clinical Pharmacology and Therapeutics, characterizing dose-escalation pharmacokinetics in healthy Chinese subjects [5]. Prior disclosures pointed to a Q2 2026 readout window for the Phase 3 program, which is now open. Topline data may be available or imminent and a refresh of this writeup is warranted once results are public. The most plausible near-term regulatory path is an NMPA submission in China; ex-China rights status is not publicly disclosed. A reasonable NMPA filing timeline, assuming a positive readout and standard CDE submission packaging, runs 6 to 12 months after topline, putting potential filing in late 2026 to mid-2027.

GLP-1, short for glucagon-like peptide-1, is a hormone gut cells release within minutes of eating. It tells the pancreas to release insulin in response to the meal, suppresses glucagon (the hormone that pushes blood sugar up), slows stomach emptying so glucose enters the bloodstream more gradually, and signals satiety to the brain. In type 2 diabetes the response to native GLP-1 is blunted and insulin secretion is sluggish, so activating the GLP-1 receptor (GLP1R) pharmacologically corrects multiple defects at once. Exendin-4 is a peptide originally isolated from Gila monster saliva that hits the same receptor as GLP-1 but resists DPP-4, the enzyme that chews up native GLP-1 within minutes. The first GLP-1 drug ever approved, exenatide (Byetta), was simply synthetic exendin-4. JY09 takes two copies of exendin-4 and fuses them to a human IgG antibody Fc fragment. The Fc piece is the same trick dulaglutide (Trulicity) uses: antibodies recycle through cells and stay in circulation, so an Fc fusion turns a short-lived peptide into a chronic-dosing injection. JY09's bi-weekly schedule is unusual in the class (dulaglutide and semaglutide are weekly), and if achieved with comparable steady-state coverage it is a real patient-preference lever. Target validation is as strong as it gets in metabolic disease. Counting both pure GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide, exenatide, lixisenatide) and the GLP-1/GIP dual agonist tirzepatide, the broader incretin class generated roughly $50 billion in combined branded revenue in 2024 across Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Victoza, and others, with roughly $30 to 35 billion of that traceable to pure GLP-1 agonists and the balance to tirzepatide [7]. The distinction matters: tirzepatide's superior weight and HbA1c results come from dual GIP+GLP-1 engagement, not from being a better GLP-1 agonist, so it sets a commercial bar that pure GLP-1 entrants like JY09 cannot fully chase on mechanism alone. The mechanism works. The open question is whether JY09's specific dimer-Fc design matches the potency, tolerability, and dose profile of incumbent products.

NCT06257966 is the commercially relevant readout. It enrolled 600 T2DM patients inadequately controlled on metformin in a 1:1:1 randomization to JY09 1.2 mg bi-weekly, JY09 2.4 mg bi-weekly (with two-week dose escalation), or dulaglutide as an active comparator over 52 to 54 weeks [1]. Primary endpoint is change in HbA1c, the standard regulatory endpoint for diabetes drugs. Picking dulaglutide as the comparator is a deliberate choice: same class, structurally analogous as a peptide-Fc fusion, and the most widely used weekly GLP-1 in China at trial start. A clean non-inferiority result against dulaglutide would justify approval as a same-class alternative. Superiority on HbA1c or weight loss would be a stronger commercial story but harder to hit. The bi-weekly versus weekly schedule difference is also a real differentiator on patient burden if the efficacy numbers land non-inferior. NCT06254014 is the supportive 270-patient placebo-controlled trial, which establishes absolute efficacy versus standard-of-care without rescue [2]. Both trials list status as active not recruiting, meaning enrollment is closed and patients are in follow-up. Design limits worth flagging: the trials are Chinese-population studies, so data will support an NMPA filing cleanly but may not transfer to FDA or EMA submissions without bridging work. Background therapy in NCT06257966 was metformin alone, while in current clinical practice many T2DM patients are on SGLT2 inhibitors or insulin, so the result will not directly speak to add-on use against modern regimens. Sample size is appropriate for HbA1c non-inferiority but too small to detect cardiovascular outcomes, which is fine for initial approval but limits the label. Pre-specified secondary endpoints (including whether body weight change is on the list) are not visible in the public trial summary; pulling those from the full protocol is the gating step before reading any secondary signal, and a GLP-1 Phase 3 without a weight endpoint would itself be noteworthy. A separate strategic caveat: dulaglutide reaches US compound patent expiration in 2027 with biosimilar entry expected to follow [9], so a non-inferiority label against a soon-to-be-genericized comparator carries less ex-China licensing value than it would have several years ago. No published interim or topline data are available as of the most recent audit.

Our model estimates a 34% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 66%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by its light or open-label blinding; it is held back by the sponsor's thin or weak approval record, weak or limited earlier-phase results, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is moderate but real. Non-inferiority against dulaglutide is the bar in NCT06257966, and the precedent of GSK's albiglutide (Tanzeum), an exendin-based Fc-fusion GLP-1 agonist withdrawn from the US market in 2017, is worth flagging. Albiglutide's failure was primarily an efficacy problem: head-to-head data through three years of HARMONY follow-up showed HbA1c reductions of roughly 0.3% to 0.9%, weaker than liraglutide and dulaglutide at approved doses, with substantially smaller weight loss [8]. It launched into a market where semaglutide was already outperforming, and GSK pulled the product despite a positive cardiovascular outcomes trial. Whether JY09 has enough potency at its chosen dose to match dulaglutide is the central efficacy question for this readout, and there is no public Phase 2 dose-finding data to anchor expectations. Safety risk centers on the GI tolerability profile common to all GLP-1 agonists (nausea, vomiting, diarrhea), which can cause discontinuation. Immunogenicity is a real but separate concern that applies to exendin-4 backbones specifically: exenatide (Byetta) had documented anti-drug antibody formation in a meaningful fraction of patients, and any exendin-derived candidate inherits that question. For albiglutide, immunogenicity was a secondary issue rather than the proximate cause of withdrawal, so it is not appropriate to lump these two failure modes together. Pancreatitis and gallbladder events are class warnings but historically have not been deal-breakers at the regulatory level. Execution risk is contained: enrollment is closed and follow-up is the remaining step. The bigger execution concern is sponsor capability for global commercialization, since Beijing Dongfang Biotech has no marketed products. Commercial risk is the dominant problem. Even with a clean approval, JY09 enters a market where semaglutide injectable and oral, tirzepatide, and emerging multi-agonists like retatrutide set the efficacy bar. In China specifically, generic semaglutide is on the way once patents expire. JY09 needs a clear price, supply, or convenience advantage to take meaningful share, and bi-weekly dosing is the most concrete structural lever currently visible.

Watch for the NCT06257966 readout, expected Q2 2026 and now overdue or imminent. The single data point that matters: HbA1c reduction at the primary timepoint, JY09 versus dulaglutide. A non-inferiority margin held with comparable GI tolerability and no immunogenicity surprise turns this into a viable China-market product, with bi-weekly dosing as a real patient-preference selling point against weekly competitors. A miss on non-inferiority effectively ends the program's commercial story, since the GLP-1 class has moved well past dulaglutide-level efficacy. Weight loss, if it is included as a pre-specified secondary endpoint (the public trial summary does not confirm this and the full protocol is the source of truth), would be the second number to scan; a numerical edge against dulaglutide could open obesity as a follow-on indication, where the commercial math is far better. BioCosm has no current visibility into whether the sponsor is pursuing a separate obesity-indication program for JY09. China's adult diabetes population is approximately 140.9 million (IDF Diabetes Atlas 2021), the largest in the world and significantly underpenetrated by injectable GLP-1 agonists due to cost and supply constraints, so a price-competitive domestic product with a less burdensome dosing schedule has a real addressable population even without export rights [10]. Beijing Dongfang Biotech is privately held and does not file SEC reports, so financial disclosures will be limited to Chinese-language press releases and CDE submissions. There is no listed Western partner. For investors and BD teams, the realistic value is as an ex-China license opportunity if the data are clean, but the buyer pool is small given how saturated the Western GLP-1 market already is with Lilly and Novo, and dulaglutide itself enters US patent expiration in 2027 [9], which softens the comparative pitch further. Check back when the NCT06257966 topline is published; until then, this is a holding-pattern node. The broader signal worth tracking is the maturation of the Chinese GLP-1 pipeline. Multiple domestic sponsors are running parallel head-to-heads against dulaglutide and semaglutide. Whoever lands first with clean superiority or a differentiated dosing profile reshapes the China diabetes and obesity market on a 3- to 5-year horizon.